Gut Bacterial Metabolite Shapes Brain Damage After Stroke, Study Finds

A stroke unfolds in minutes, but its ultimate consequences are decided over hours and days by processes that extend far beyond the blocked or ruptured blood vessel at its center. How much brain tissue survives depends not only on how quickly circulation can be restored but also on the immune response that the body mounts in the aftermath of the injury. Now, researchers at the Institute for Stroke and Dementia Research (ISD) at LMU Klinikum in Munich have identified an unexpected participant in that response: a metabolite produced by bacteria living in the gut. The finding, published in the journal Cell, reveals a concrete molecular pathway by which the intestinal microbiota can influence the severity of brain damage after stroke, and it raises the provocative possibility that the microbiome could one day be deliberately manipulated to protect the brain.

The team, led by Dr. Corinne Benakis, set out to understand how signals originating in the intestine reach the immune cells that help determine stroke outcome. Their starting point was an observation in mouse models of severe stroke: bacteria capable of producing a metabolite called indole became more abundant in the gut following the injury. Indole is a small molecule with a distinctive property that makes it a plausible messenger between microbes and the body — it is produced only in the gut, by bacteria that carry a gene known as tnaA. That gene encodes an enzyme allowing these microbes to convert tryptophan, an amino acid obtained from food, into indole. In other words, a dietary building block is transformed by bacterial metabolism into a signaling molecule that can act on the host immune system.

When the researchers examined what this meant for the brain, the results were striking. In mice, the presence of indole-producing bacteria worsened brain injury after stroke. This established a causal link rather than a mere correlation: the microbial metabolite was not simply a byproduct of the disease state but an active participant in shaping how much damage the stroke inflicted. The discovery adds stroke to a growing list of conditions in which gut-derived molecules have been shown to reach beyond the digestive tract and influence distant organs, often through the immune system.

The next question was mechanistic: how does a molecule made in the gut alter events in the brain? The answer lies with a receptor called the aryl hydrocarbon receptor, or AHR, a sensor found in dendritic cells. Dendritic cells are immune sentinels that patrol the intestinal lining, sampling their surroundings and helping to coordinate immune responses throughout the body. Indole, the team found, acts on AHR in these cells, and that interaction changes their behavior in ways that matter for stroke recovery.

To test this directly, the researchers switched off AHR specifically in dendritic cells. The effect on the mice was protective: without the receptor, they were better shielded against brain injury after stroke. The reason, according to the study, lies in how the cells behave once the indole signal is removed. Dr. Rosa Delgado Jiménez, who shares first authorship of the paper with Alexandria Ruggles and Mujeeb Adedokun, described the change in vivid terms. Dendritic cells, she explained, have long extensions, like arms, that allow them to sense changes in their environment, including metabolites produced by gut bacteria. When AHR was switched off, the behavior of these cells changed completely: they became more potent at migrating from the intestine to the meninges, the membrane surrounding the brain.

That migration proved to be consequential. Once in the meninges, the dendritic cells promoted protective T cells, a class of immune cells capable of dampening inflammation and tissue damage, and thereby helped reduce the injury in the brain. The picture that emerges is a chain of events running from the dinner plate to the brain’s outer membranes: dietary tryptophan is converted by tnaA-carrying bacteria into indole; indole engages AHR in intestinal dendritic cells; that engagement restrains the cells from migrating and from fostering protective T cells; and the resulting immune balance tilts toward greater brain damage after a stroke. Blocking the receptor breaks the chain at its immunological link and tips the balance back toward protection.

Crucially, the researchers found evidence that this pathway may not be a peculiarity of mice. In a cohort of human patients with ischemic stroke, the ISD team observed that a higher abundance of bacterial TnaA — the gene that enables indole production — was associated with poorer functional outcome. The patient samples for this analysis were provided by collaborating teams led by Fernández-Cadenas in Barcelona and Lorenz Hirt in Lausanne. The human data, while correlational, align with the mouse experiments and suggest that the same microbial machinery could be operating in people, influencing how well patients recover from stroke in the real world.

The study also uncovered a connection to stroke risk factors themselves. Bacteria carrying the tnaA gene and capable of producing indole were more abundant in people with conditions known to raise stroke risk, including obesity and type 2 diabetes. This observation hints at a possible mechanism by which metabolic disease could prime the immune system for a worse response to brain injury, though the researchers are careful to note that much remains to be established about whether the full pathway identified in mice also operates in patients.

The complexity of the work made collaboration essential. The study drew on the Transregional Collaborative Research Centre TRR 355, a research network funded by the German Research Foundation (DFG) that focuses on regulatory T cells. Benakis emphasized that the project required expertise a small group could not have covered alone: the TRR 355 network provided financial support and access to the knowledge of group leaders within the consortium. In addition, the team worked with Michael Zimmermann at EMBL and Michael Gigl at TUM to detect tryptophan metabolites and microbial indole, measurements that are technically challenging because of the low concentrations and complex chemistry involved. It was, as Benakis put it, a real team effort.

Beyond its immediate findings, the study opens a question that could reshape how scientists think about stroke prevention: could changing the gut microbiome, or the metabolites it produces, in healthy individuals help prepare the immune system to respond differently if a stroke occurs? Most stroke research and therapy focuses on the brain itself — clot removal, neuroprotection, rehabilitation — while the systemic immune context in which the injury unfolds has received far less attention as a target. If the gut’s contribution proves as influential in humans as it appears to be in mice, interventions ranging from diet to microbial or metabolic therapies could conceivably be used to tilt the immune system toward a protective configuration before a stroke ever happens, particularly in people at elevated risk. As Delgado Jiménez observed, stroke is usually thought of as an injury restricted to the brain, but the findings show that the gut can help shape the immune response to that injury. Benakis noted that the team still needs to determine whether the mechanism identified in mice also occurs in patients, but the work opens new avenues for investigating whether the gut microbiota could eventually be targeted to improve stroke outcome, including through preventive approaches in those most vulnerable.

Subject of Research: How the gut bacterial metabolite indole influences immune responses and brain damage after stroke

Article Title: How gut bacteria can shape the brain’s response to stroke

Article References: How gut bacteria can shape the brain’s response to stroke. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: stroke, gut microbiota, indole, tryptophan, aryl hydrocarbon receptor, dendritic cells, T cells, meninges, ischemic stroke, tnaA, immune response, LMU